A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC1031) with Gemcitabine in patient with metastatic pancreatic carcinoma.

Trial Profile

A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC1031) with Gemcitabine in patient with metastatic pancreatic carcinoma.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs NUC 1031 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms ACELARATE
  • Most Recent Events

    • 20 Jan 2018 To date, 85 patients have been randomised, according to the trial design presented at the 2018 Gastrointestinal Cancers Symposium
    • 20 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium
    • 06 Dec 2015 Status changed from not yet recruiting to recruiting, according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top